Effect of Anti-Membrane Antibody-Methotrexate Conjugate on Prostate Tumors
Author Information
Author(s): A.J. Rowland, M.E. Harper, D.W. Wilson, K. Griffiths
Primary Institution: Tenovus Institute for Cancer Research, University of Wales College of Medicine
Hypothesis
Can methotrexate conjugated to an anti-membrane antibody effectively target and reduce the growth of human prostate tumors?
Conclusion
The anti-membrane antibody-methotrexate conjugates significantly inhibited tumor growth in mice compared to other treatments.
Supporting Evidence
- Conjugates showed a 16-fold greater accumulation of methotrexate in tumor tissue compared to free drug.
- Significant reductions in tumor growth rates were observed with the conjugates compared to controls.
- The conjugates retained approximately 68% of their ability to inhibit dihydrofolate reductase.
Takeaway
This study shows that a special drug linked to an antibody can help kill prostate cancer cells better than the drug alone.
Methodology
The study involved in vitro and in vivo experiments using PC3 prostate cancer cells and athymic nude mice to assess the effectiveness of the conjugate.
Limitations
The antibody used was not specific to prostate cells, which may affect targeting efficiency.
Participant Demographics
Athymic nude mice bearing PC3 tumors.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Want to read the original?
Access the complete publication on the publisher's website